Tandem Diabetes Acquires Swiss Based Insulin Patch Pump Developer
Tandem Diabetes Care Inc (NASDAQ:TNDM) has agreed to acquire AMF Medical SA, the privately held Swiss developer of the investigational Sigi…
Psychedelic Company Sale: Mydecine Gets Over $2.5M For Wholly-Owned Tech Subsidiary Business
Mydecine Innovations Group Inc.
Aesther Healthcare Acquisition Corp. Announces Intention To Extend Period To Consummate Business Combination
New York, NY and Providence, RI, Dec. 13, 2022 (GLOBE NEWSWIRE) -- As previously announced, on August 31, 2022, Aesther Healthcare Acquisition Corp. ("Aesther") (NASDAQ:AEHA) entered into definitive merger
Lifezone Metals, Developer Of Cleaner Metals For EV Batteries, To Be Listed On NYSE Via Combination With GoGreen Investments
Highlights
Controlling interest in one of world's largest and highest-grade undeveloped nickel deposits offers new resource of more sustainable metals, addressing critical supply deficit for EV
Bausch Health Investors Request Blocking Eye-Care Business Spinoff, Alleging Protection From Lawsuits
More than 50 funds that own Bausch Health Companies Inc (NYSE: BHC) investors are reportedly seeking to block the eye-care business spin-off, Bausch + Lomb Corp (NYSE: BLCO).
Tandem Diabetes Care to Acquire Insulin Patch Pump Developer, AMF Medical; Includes Previous Investment Of CHF 8M, Cash Payment Of CHF 26.4M Due At Closing, Additional Contingent Payments Of Up To CHF 129.6M
Terms of the Agreement
Tandem Diabetes Care will acquire AMF Medical under the following financial terms of the agreement:
A previous strategic investment of Swiss Francs ("CHF") 8.0 million paid in
Shell Announced Earlier Agreement to Sell Non-operated Interests in Malaysia’s Baram Delta for Base Consideration of $475M
Sarawak Shell Berhad ("SSB"), a subsidiary of Shell plc, has agreed to sell its stake in two offshore production sharing contracts (PSC) in the Baram Delta to Petroleum Sarawak Exploration & Production Sdn. Bhd. ("PSEP").
Reported Late Monday, ZyVersa Therapeutics Inc. And Larkspur Health Acquisition Corp. Close Business Combination; ZyVersa Expected To Begin Trading On Nasdaq December 13, 2022 Under Ticker “ZVSA”
ZyVersa is a clinical stage biopharmaceutical company developing first-in-class product candidates for treatment of renal and inflammatory diseases
WESTON, Fla. and BRIDGEWATER, N.J., Dec. 12,